ABT
Abbott Laboratories
NYSE · Healthcare · Medical - Devices · US
$108.99
+0.18%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 46.6B | 44.3B | 42.0B | 40.1B | 43.7B |
| Cost of Revenue | 20.1B | 19.7B | 20.6B | 20.1B | 21.3B |
| Gross Profit | 26.5B | 24.6B | 21.3B | 20.0B | 22.3B |
| Operating Expenses | |||||
| R&D Expense | 3.2B | 3.0B | 2.8B | 2.7B | 2.9B |
| SG&A Expense | 13.5B | 12.4B | 11.7B | 10.9B | 11.1B |
| General & Admin Expense | 3.1B | 12.4B | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 1.9B | 1.3B | — | — | — |
| Total Operating Expenses | 18.6B | 16.6B | 14.5B | 13.6B | 14.0B |
| Cost and Expenses | 38.7B | 36.3B | 35.1B | 33.7B | 35.3B |
| Operating Income (EBIT) | 7.9B | 8.0B | 6.8B | 6.4B | 8.4B |
| Non-Operating | |||||
| Interest Income | 261.0M | 230.0M | 344.0M | 385.0M | 183.0M |
| Interest Expense | 637.0M | 341.0M | 603.0M | 698.0M | 315.0M |
| Net Interest Income | (376.0M) | (111.0M) | (259.0M) | (313.0M) | (132.0M) |
| Other Non-Op Income/Expense | (421.0M) | 418.0M | 188.0M | 229.0M | (56.0M) |
| Non-Operating Income (excl Interest) | (68.0M) | (759.0M) | (765.0M) | (927.0M) | (259.0M) |
| EBT (Pre-Tax Income) | 7.5B | 8.5B | 7.0B | 6.7B | 8.3B |
| Income Tax Expense | 2.1B | 1.9B | (6.4B) | 941.0M | 1.4B |
| Bottom Line | |||||
| Net Income | 5.4B | 6.5B | 13.4B | 5.7B | 6.9B |
| Earnings from Cont. Ops | 5.4B | 6.5B | 13.4B | 5.7B | 6.9B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 5.4B | 6.5B | 13.4B | 5.7B | 6.9B |
| Per Share | |||||
| Basic EPS | $3.11 | $3.74 | $7.67 | $3.30 | $3.94 |
| Diluted EPS | $3.11 | $3.72 | $7.64 | $3.27 | $3.91 |
| Revenue Per Share | $26.73 | $25.37 | $24.22 | $23.13 | $24.90 |
| Shares | |||||
| Basic Shares Outstanding | 1.7B | 1.7B | 1.7B | 1.7B | 1.8B |
| Diluted Shares Outstanding | 1.7B | 1.7B | 1.7B | 1.7B | 1.8B |
| Profitability Metrics | |||||
| EBITDA | 9.9B | 11.6B | 10.8B | 10.6B | 11.9B |
| D&A | 1.9B | 2.7B | 3.2B | 3.2B | 3.3B |
| EBIT | 8.0B | 8.8B | 7.6B | 7.4B | 8.6B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026